Compressed Sensing Applied to Weather Radar

We propose an innovative meteorological radar, which uses reduced number of spatiotemporal samples without compromising the accuracy of target information. Our approach extends recent research on compressed sensing (CS) for radar remote sensing of hard point scatterers to volumetric targets. The previously published CS-based radar techniques are not applicable for sampling weather since the precipitation echoes lack sparsity in both range-time and Doppler domains. We propose an alternative approach by adopting the latest advances in matrix completion algorithms to demonstrate the sparse sensing of weather echoes. We use Iowa X-band Polarimetric (XPOL) radar data to test and illustrate our algorithms.Comment: 4 pages, 5 figrue

Estimation of outgassing from an expended apogee motor and its effects on spacecraft surfaces

An experimental and theoretical investigation was carried out to evaluate the degradation of the solar cells and other sensitive surfaces of a spacecraft, resulting from the molecular outgassing of an expended solid propellant apogee motor. The motor, following its burnout, is retained by the spacecraft and is a source of gases and particulates which will be released mainly by the unburned propellant-to-casing insulation. The deployment of the solar array within a few minutes after the motor burn results in the interception and reflection to the surfaces of the spacecraft of the molecular outgassing and particulates. Various methods, based on some experimental data, were used to analytically assess the magnitude of the outgassing from the engine

Nanocrystalline iron at high pressure

X-ray diffraction measurements were performed on nanocrystalline iron up to 46 GPa. For nanocrystalline epsilon-Fe, analysis of lattice parameter data provides a bulk modulus, K, of 179±8 GPa and a pressure derivative of the bulk modulus, K[prime], of 3.6±0.7, similar to the large-grained control sample. The extrapolated zero-pressure unit cell volume of nanocrystalline epsilon-Fe is 22.9±0.2 Å^3, compared to 22.3±0.2 Å^3 for large-grained epsilon-Fe. No significant grain growth was observed to occur under pressure

Canagliflozin for the Treatment of Diabetic Kidney Disease and Implications for Clinical Practice: A Narrative Review

Type 2 diabetes mellitus (T2DM) affects millions of people worldwide, elevating their risk of developing a range of complications, including chronic kidney disease (CKD). People with T2DM and CKD (i.e., diabetic kidney disease, DKD) have an increased risk of progressing to end-stage kidney disease (ESKD), experiencing cardiovascular complications, and premature death. Despite this, DKD is primarily addressed through management of risk factors, and there are few pharmaceutical treatments capable of reversing or delaying disease progression. Canagliflozin is a sodium glucose co-transporter 2 inhibitor that was initially developed as a blood glucose-lowering agent for people with T2DM. Evidence from clinical trials of canagliflozin in people with T2DM, as well as evidence from cardiovascular outcomes trials in people with T2DM and high cardiovascular risk, provided preliminary evidence suggesting that it may also have beneficial renal effects. The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial was a dedicated renal outcomes trial of canagliflozin that assessed its renal effects in people with DKD. Overall, the CREDENCE trial demonstrated that canagliflozin improves renal outcomes and slows early disease progression in people with DKD. These data supported the approval of canagliflozin for the treatment DKD, the first new treatment in almost 20 years; therefore, it is important for clinicians to understand how to implement this treatment in their clinical practice

Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials

Background: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is paramount to determine the relationship between these two diseases. Purpose: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug Administration published guidance for manufacturers on antihyperglycemic agents, requiring studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents have conducted and published results from CV outcomes trials (CVOTs), with more trials due to publish soon. This review discusses the relationship between CVD and T2D and explores findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their prescribing patterns for patients with T2D. Conclusion: Patients with T2D are at high risk of CVD, so CV risk should be carefully considered when managing these patients, and CV risks and benefits of antidiabetic drugs should be included in prescribing decisions

Correlation between body condition score and body composition in a rat model for obesity research

fals